This is an open-label, 104-week, multicenter, extension study designed to evaluate the
long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or
80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the
preceding studies, D1050301, D1050325, and D1050326